Akademik Veri Yönetim Sistemi
TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES, cilt.13, sa.3, ss.351-357, 2016 (ESCI)
Due to the increase of cancer incidence in recent years, contemporary studies have focused on the identification, diagnosis and treatment of this disease. It is rather difficult to treat cancer without harming normal cells. Thus, studies exploring nano systems that are targeted to the cancerous cells are drawing attention. The frequent formation of metastasis in the bone tissue of certain cancers, such as the breast and prostate, has increased the mortality risk from these cancers. For this reason, preventing metastasis by targeting metastatic bone tissue with anti-neoplastic agents without damaging healthy soft tissue has become a subject of interest for many researchers. In addition to the therapeutic properties of bisphosphonates for bone metastases that form osteoclastic and osteoblastic, its affinity to hydroxyapatite, the main mineral of bone tissue, has been extensively studied as a targeting agent for bone diseases. With the conjugation of bisphosphonates to the nanoparticulate systems, nanoparticles loaded with the active ingredient are transmitted solely to the diseased bone tissue. Then, with the help of a nanostructured system, the bisphosphonates are localized only in the tumor containing diseased bone tissue, and the chemotherapeutic agent is released in a controlled manner. In this review, current approaches targeting bone metastases, and especially studies conducted with nanostructured drug carrier systems, are assessed.